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BACKGROUND: Cytochrome P450 2D6 (CYP2D6) has a crucial role in the metabolic conversion of tamoxifen into the active
metabolite endoxifen. In this cohort study, the effect of CYP2D6-predicted phenotype, defined as the combined effect of CYP2D6
genetic variation and concomitant use of CYP2D6-inhibiting medication, on time to breast cancer progression (TTP) and overall
survival (OS) in women who use tamoxifen for metastatic breast cancer (MBC) was examined.
METHODS: We selected patients treated with tamoxifen (40mg per day) for hormone receptor-positive MBC from whom a blood
sample for pharmacogenetic analysis (CYP2D6*3, *4, *5, *6, *10 and *41) was available. Patient charts (n¼102) were reviewed to
assess TTP and OS, and to determine whether CYP2D6 inhibitors were prescribed during tamoxifen treatment.
RESULTS: OS was significantly shorter in patients with a poor CYP2D6 metaboliser phenotype, compared with extensive metabolisers
(HR¼2.09; P¼0.034; 95% CI: 1.06–4.12). Co-administration of CYP2D6 inhibitors alone was also associated with a worse OS
(HR¼3.55; P¼0.002; 95% CI: 1.59–7.96) and TTP (HR¼2.97; P¼0.008; 95% CI: 1.33–6.67) compared with patients without
CYP2D6 inhibitors.
CONCLUSION: CYP2D6 phenotype is an important predictor of treatment outcome in women who are receiving tamoxifen for MBC.
Co-administration of CYP2D6 inhibitors worsens treatment outcome of tamoxifen and should therefore be handled with care.
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INTRODUCTION
Breast cancer is the most common type of cancer among women
worldwide with nearly 1.2 million new diagnoses each year
(Kamangar et al, 2006). Tumour expression of the oestrogen
receptor (ER) and/or progesterone receptor (PR) has an important
role in the choice for systemic treatment. In ER-positive and/or
PR-positive breast cancer, anti-oestrogenic therapy has proven
efficacy in both the adjuvant and metastatic setting (Riggs and
Hartmann, 2003).
Tamoxifen is a so-called selective oestrogen-receptor modifier
(Mortimer et al, 2007) with potent anti-oestrogenic action, which
competes with oestrogen at the ER, resulting in the inhibition of
growth of ER-positive breast cancer cells (Riggs and Hartmann,
2003). The hormonal receptor status therefore is an important
predictive factor for the response of tamoxifen in breast cancer
(Fisher et al, 2005). Tamoxifen is considered a pro-drug,
metabolised by phase I enzymes (cytochrome P450 (CYP2D6)
iso-enzymes 3A4, 2D6 and others) into metabolites including
N-desmethyl-tamoxifen (NDM-TAM), 4-hydroxy-tamoxifen
(4-OH-TAM) and finally the more potent metabolite 4-hydroxy-
NDM-TAM(endoxifen). Both 4-OH-TAM and endoxifen are
known to have a 30–100 times higher anti-oestrogen activity
than tamoxifen. However, on average, plasma concentrations
of endoxifen are approximately 10 times higher than those of
4-OH-TAM, making endoxifen the most potent metabolite of
tamoxifen (Borges et al, 2006). In addition, endoxifen was recently
proven to be the most potent metabolite in tamoxifen therapy
with respect to the growth inhibition of breast cancer cells
(Wu et al, 2009). Cytochrome P450 2D6 has a crucial role in the
formation of endoxifen (Goetz et al, 2008). The activity of this
enzyme is partly determined by the presence of polymorphisms in
the CYP2D6 gene, resulting in differences in the metabolising
capacity. On the basis of CYP2D6-metabolising capacity, the
population can be divided into four phenotypes. Ultrarapid
metabolisers have duplicated CYP2D6 genes, and thus
express excessive amounts of functional enzyme. Carriers of two
functional alleles exhibit normal enzyme activity and are classified
as extensive metabolisers (EMs). Patients with one functional
and one non-functional allele or two decreased activity alleles
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sare referred to as intermediate metabolisers (IMs). Individuals
with two non-functional alleles of the gene lack CYP2D6 enzy-
matic activity and, therefore, are classified as poor metabolisers
(PMs). In Caucasians, CYP2D6*4 allele is the most common
non-functional allele, having an allele frequency of about
20% (Bradford, 2002). Other dysfunctional alleles that are (less
frequently) seen in the Caucasian population are CYP2D6*3,
CYP2D6*5 and CYP2D6*6, with allele frequencies of 1–2%, 2–7%
and 1%, respectively, (Bradford, 2002).
A few years ago, an association between CYP2D6 genotype
and clinical outcome in tamoxifen-treated breast cancer
patients was described by Goetz et al (2005). Postmenopausal
women with the homozygous CYP2D6*4 genotype (PM)
using tamoxifen tend to have a higher risk of breast
cancer recurrence than EMs. This finding was confirmed by
Schroth et al (2007) in a retrospective study among patients using
tamoxifen as an adjuvant therapy and by Newman et al (2008).
Women with the dysfunctional CYP2D6 alleles *4, *5, *10 and *41
had an increased risk of breast cancer recurrence and worse
relapse-free survival rates. More recently, a multicenter study
including retrospectively and prospectively collected patient data
also confirmed an association between CYP2D6 variation and
clinical outcome in women receiving adjuvant tamoxifen (Schroth
et al, 2009). However, also negative results or even opposite
findings have been published (Nowell et al, 2005; Wegman et al,
2005, 2007) and recently reviewed (Dezentje et al, 2009; Hoskins
et al, 2009).
Besides the CYP2D6 genotype, concomitant use of CYP2D6-
inhibiting medication may also be an important factor influencing
the clinical outcome of tamoxifen treatment. Important CYP2D6-
inhibiting drugs are, for instance, selective serotonin reuptake
inhibitors (SSRIs), which may be used in breast cancer patients to
treat depression or hot flashes; a common side effect of tamoxifen
(Loprinzi et al, 2000). Goetz et al (2007) have shown that poor
CYP2D6 metabolisers, due to genetic polymorphisms and/or
CYP2D6-inhibiting medication (further defined as ‘predicted
phenotype’), using tamoxifen as adjuvant therapy do have a
significantly shorter time to breast cancer recurrence than EMs.
Furthermore, a presented review of medical records involving
breast cancer patients treated with tamoxifen showed that
concomitant use of CYP2D6-inhibiting medication increased the
risk of breast cancer recurrence (Aubert et al, 2009). In addition, in
a recently published cohort study, paroxetine use during
tamoxifen treatment was associated with an increased risk of
death from breast cancer (Kelly et al, 2010). In contrast, Dezentje
et al (2010)reviewed Dutch pharmacy data and reported opposite
findings. They found no evidence that CYP2D6 inhibitors increase
the risk of breast cancer recurrence.
These available results clearly warrant further research to test
the hypothesis whether CYP2D6 phenotype is associated with the
clinical outcome in tamoxifen-treated breast cancer patients.
Moreover, studies in patients with metastatic disease are very
scarce. To our knowledge, so far only one study reported on the
effect of CYP2D6 genotype in a small number of Asian breast
cancer patients using tamoxifen for metastatic disease evaluating
the association of the dysfunctional allele CYP2D6*10/*10 (com-
monly occurring in the Eastern people in contrast to Caucasians)
with clinical outcome (Lim et al, 2007). It was found that the PM
phenotype based on genotype was associated with a significantly
shorter time to progression (TTP). A correlation between CYP2D6
phenotype, and clinical outcome in metastatic breast cancer (MBC)
patients of Caucasian origin has not been described yet. Therefore,
the present study aimed to investigate the effect of CYP2D6-
predicted phenotype, defined as the combined effect of the most
common CYP2D6 genetic polymorphisms in Caucasians (*3, *4,
*5, *6, *10 and *41) and concomitant use of CYP2D6-inhibiting
medication, on TTP and overall survival (OS) in female MBC
patients treated with tamoxifen.
MATERIALS AND METHODS
Patients and study design
A consecutive series of patients treated with tamoxifen for breast
cancer at the Daniel den Hoed cancer centre of the Erasmus MC
University hospital, were sampled for pharmacogenetic analysis
between 2000 and 2008. From that dataset we selected all patients
with MBC, having a positive hormone receptor status (ER
and/or PR), and receiving a tamoxifen dose of 40mg per day. In
The Netherlands, 40mg per day is the standard tamoxifen dose
for MBC patients compared with 20mg per day in the adjuvant
setting. As the terminal elimination half-life of tamoxifen for a
single dose is 5–7 days, and the time to reach steady state plasma
concentrations is 3–4 weeks, an observational period of 1 month
may be necessary before the effect of hormonal therapy can be
seen (Morello et al, 2003). Therefore, participants using tamoxifen
for o30 days were also excluded. Patients started with tamoxifen
between 1986 and 2008. This study was approved by the local
medical ethics board (study numbers AZR00/168A and MEC02/
1002), and all patients gave written informed consent. Patient
charts were reviewed to record the following data: age at start of
tamoxifen therapy for metastatic disease, race, ER and PR status,
treatments before tamoxifen therapy, number and location of
metastatic sites, CYP2D6-inhibiting co-medication, TTP and OS.
Participants were monitored from the start of first tamoxifen
prescription for MBC until death, or until the end of the study
period (July 2009), whichever came first. Time to progression was
defined as the time from first tamoxifen prescription for MBC to
the documentation of progression, which was assessed by standard
RECIST criteria (Hayward et al, 1977). Overall survival was defined
as the time from first tamoxifen prescription for MBC to death due
to any cause.
Patient charts were also reviewed to determine whether the
following known CYP2D6 inhibitors were co-administered during
the time that tamoxifen was used for metastatic disease: fluoxetine,
paroxetine and bupropion (all strong inhibitors), duloxetine and
terbinafine (moderate inhibitors), amiodarone, cimetidine, citalo-
pram and sertraline (all weak inhibitors) (Flockhart, 2007).
CYP2D6 genotyping
All patients were genotyped for the CYP2D6*3, *4, *5 and *6
polymorphisms, which will detect over 95% of CYP2D6 PMs and
also for the CYP2D6 polymorphisms *10 and *41 that are
associated with reduced enzyme activity. The source of genomic
DNA was EDTA blood and the genotyping was done using Taqman
allelic discrimination assays on the ABI Prism 7000 (Applied
Biosystems, Nieuwerkerk aan den IJssel, the Netherlands)
Sequence detection system. Primers and probes were designed
by Applied Biosystems using their Assay-by-Design service.
Polymerase chain reactions (PCR) were carried out in a reaction
volume of 10.0ml, containing assay-specific primers, allele-specific
Taqman MGB probes (Applied Biosystems), Abgene Absolute
QPCR Rox Mix (Applied Biosystems) and genomic DNA (1ng).
The thermal profile consisted of an initial denaturation step at
951C for 15min, followed by 40 cycles of denaturation at 921C for
15s and annealing and extension at 601C for 1min. The *5 was
determined using long range PCR on 20ng genomic DNA using
primers 50-CACACCGGGCACCTGTACTCCTCA-30,5 0-CAGGCATG
AGCTAAGGCACCCAGAC-30,5 0GTTATCCCAGAAGGCTTTGCAG
GCTTCA-30 and 50-GCCGACTGAGCCCTGGGAGGTAGGTA-30
with PCR profile 7min 941C, followed by 35 cycles of 1min
941C, 1min 651C annealing and 5min 681C elongation using rTth
DNA polymerase (Applied Biosystems). PCR products were
analysed on an EtBr gel. Presence of a CYP2D6 gene deletion
(*5) can be observed by the presence of a 3.5kb fragment. A 5.1kb
fragment will always be amplified, and serves as an internal
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scontrol. Genotypes were scored through measuring allele-specific
fluorescence using the SDS 2.2.2 software for allelic discrimination
(Applied Biosystems).
CYP2D6 phenotyping
On the basis of CYP2D6 genotype in combination with
concomitant use of CYP2D6-inhibiting medication, patients were
classified into three phenotype groups (see Table 2). As an
observational period of 3 or even 6 months may be necessary
before the effect of hormonal therapy could be seen, concomitant
CYP2D6 inhibitor use was defined as a minimum of 6 months
overlap between tamoxifen and the CYP2D6 inhibitor (Muss et al,
1994). Women without a dysfunctional (CYP2D6*3, *4, *5 or *6)
allele and who were not using a CYP2D6 inhibitor for at least 6
months (or until tamoxifen was stopped) were defined as EMs.
Intermediate metabolisers (i) carry CYP2D6*10 or *41 alleles either
homozygous or in combination with a dysfunctional allele or
(ii) were heterozygous for the CYP2D6*3, *4, *5 or *6 allele (*3/wt,
*4/wt, *5/wt or *6/wt) and did not use a CYP2D6 inhibitor or
(iii) had no dysfunctional alleles but were using a weak or
moderate CYP2D6 inhibitor. Women classified as PMs had (i) two
dysfunctional alleles (for example, CYP2D6*3/*3, *3/*4 or *4/*4),
or (ii) one dysfunctional allele (CYP2D6*3/wt, *4/wt, *5/wt or
*6/wt) with concurrent use of a moderate CYP2D6 inhibitor or
(iii) a functional genotype (wt/wt) with co-administration of a
strong CYP2D6 inhibitor (Goetz et al, 2007).
Statistical analysis
Deviations from Hardy–Weinberg equilibrium and differences in
allele frequencies of the CYP2D6*3, *4, *5, *6, *10 and*41 alleles
were analysed using w
2-tests. The effect of CYP2D6 genotype,
CYP2D6-inhibiting co-medication and CYP2D6 phenotype (EM,
IM, PM) on TTP and OS was assessed using Cox proportional
hazards models. Analyses were adjusted for age. Confounders were
adjusted for in the analysis if they caused a change in the point
estimate of more than 10 percent. Kaplan–Meier estimates and
log-rank test were used in univariate analysis of TTP and OS. The
5% cut-off level was chosen as significance level. All analyses were
carried out using SPSS software (version 15.0, Chicago, IL, USA).
RESULTS
Of the 116 patients treated with tamoxifen for MBC enroled, 104
patients had a positive hormone receptor status. Two patients
discontinued tamoxifen treatment within 30 days and were
excluded from the analysis. The characteristics of the 102 patients
treated with tamoxifen for MBC that met the inclusion criteria are
described in Table 1. Patients started with tamoxifen for metastatic
disease between 1986 and 2008. CYP2D6 genotype was determined
in 99 of these patients. In our population, the allele frequencies of
the CYP2D6*3, *4, *5, *6, *10 and*41 alleles were 3.5, 21.7, 1.5, 1.0,
1.5 and 6.6%, respectively, which is in line with earlier published
data (Bradford, 2002). Genotype distributions were in Hardy–
Weinberg Equilibrium (CYP2D6*3, *4, *5, *6, *10 and *41:
w
2¼0.46; P¼0.25). Co-administration of CYP2D6 inhibitors
(paroxetine, fluoxetine, sertraline and citalopram) occurred in
6.9% of patients (N¼7, mean duration of co-administration: 11.5
months; range: 6 months to 1.6 years).
On the basis of CYP2D6-predicted phenotype definition, 48.5%
of the patients were classified as EMs, 38.4% as IMs and 13.1% as
PMs (Table 2). Patients used tamoxifen for a mean period of time
of 2.8 years (range: 1.6 months to 17 years); being the longest
(3.0 years) in the EMs and the shortest (1.7 years) in the PMs. All
patients stopped tamoxifen because of the disease progression.
In Table 3, the associations between the predicted phenotypes
and TTP and OS, respectively, are shown. The OS in EMs and
IMs was not significantly different (HR¼0.87; P¼0.62; 95%
CI: 0.50–1.50). However, OS was significantly shorter for the PMs
compared with EMs (HR¼2.09; P¼0.034; 95% CI: 1.06–4.12).
Table 1 Baseline Characteristics
Variable
Number of patients (%)
n¼102
Age first tamoxifen use for metastatic breast cancer,
average (s.d.)
51.8 (9.1) years
Race
Caucasian 97 (95.1)
Asian 4 (3.9)
African 1 (1.0)
Previous treatments
Operative procedure
Mastectomy 41 (40.2)
Lumpectomy 53 (52.0)
None 8 (7.8)
Previous adjuvant therapy
Radiotherapy 33 (32.3)
Chemotherapy 22 (21.6)
Both chemotherapy and radiotherapy 21 (20.6)
None 26 (25.5)
Previous therapy for metastatic disease
Radiotherapy 17 (16.6)
Chemotherapy 21 (20.6)
Both chemotherapy and radiotherapy 11 (10.8)
None 53 (52.0)
No. of metastatic sites
1 69 (67.6)
2 27 (26.5)
3 6 (5.9)
Metastatic site
Lymph 27 (19.1)
Bone 62 (44.0)
Lung 30 (21.3)
Liver 13 (9.2)
Skin 8 (5.7)
Other 1 (0.7)
CYP2D6 genotypes
wt/wt 45 (44.1)
wt/*3 2 (2.0)
*3/*3 0 (0.0)
*3/*4 4 (3.9)
*3/*41 1 (1.0)
wt/*4 25 (24.5)
*4/*4 4 (3.9)
*4/*6 1 (1.0)
*4/*10 1 (1.0)
*4/*41 4 (3.9)
wt/*5 3 (2.9)
*5/*5 0 (0.0)
wt/*6 1 (1.0)
*6/*6 0 (0.0)
wt/*10 2 (2.0)
wt/*41 6 (5.9)
Unknown 3 (2.9)
CYP2D6-inhibiting co-medication 7 (6.9)
Strong 5 (4.9)
a
Moderate 0 (0.0)
Weak 2 (2.0)
b
Abbreviations: CYP2D6¼cytochrome P450 2D6; wt¼wild type.
aParoxetine
(n¼4), fluoxetine (n¼1).
bCitalopram (n¼1), sertraline (n¼1).
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sAlthough not significantly different, PMs tended to have a worse
TTP (HR¼1.69; P¼0.11; 95% CI: 0.90–3.19) compared with EMs.
As intermediate and EMs had a comparable TTP and OS, both
were taken together in the Kaplan–Meier estimates. The median
OS-time period for PMs was 5.0 years (95% CI: 4.1–5.9) compared
with 7.9 years (95% CI: 6.2–9.5) for the other predicted phenotype
groups, which is statistically significantly different (P¼0.012)
(Figure 1). For PMs, the Kaplan–Meier estimate shows a non-
significantly shorter median TTP compared with the combined
group of other predicted phenotypes (IMsþEMs), being 1.4 years
(95% CI: 0.7–2.2) vs 1.8 years (95% CI: 1.4–2.3), respectively,
(P¼0.089), as shown in Figure 1.
Although there was no significant association between CYP2D6
genotype and TTP or OS (HR¼1.29; P¼0.49; 95% CI: 0.63–2.66
and HR¼1.38; P¼0.42; 95% CI: 0.63–2.99, respectively), the
seven patients using tamoxifen together with a CYP2D6 inhi-
bitor had a significantly worse TTP (HR¼2.97; P¼0.008; 95%
CI: 1.33–6.67) and OS (HR¼3.55; P¼0.002; 95% CI: 1.59–7.96)
compared with tamoxifen users without co-administration of
CYP2D6 inhibitors (Table 4).
Previous treatment, race and number of metastatic sites, as
mentioned in Table 1, did not influence our model as a confounder
or effect modifier.
DISCUSSION
In this study, we showed that MBC patients with a positive
hormone receptor status treated with tamoxifen and having a
CYP2D6 ‘PM-predicted phenotype’ have a statistically significant
shorter OS than patients with an intermediate or extensive
phenotype. In addition, we showed that patients using tamoxifen
together with CYP2D6 inhibitors have a significantly shorter
progression-free and worse OS compared with tamoxifen users not
concomitantly using CYP2D6 inhibitors.
To our knowledge, this is the first time that the combined effect
(predicted phenotype) of genotype and/or co-medication on
tamoxifen treatment outcome has been investigated in the specific
group of hormone-sensitive MBC patients. Besides this, the FDA
approved fixed dose of tamoxifen used (40mg per day)
contributed to a homogeneous selection of patients in this study.
Most studies published focused at a tamoxifen dose of 20mg per
day. In our study, EM and IM are not significantly different in
terms of OS or TTP, although differences between these groups
have been found in other studies when the tamoxifen dose is 20mg
per day (Goetz et al, 2005; Schroth et al, 2009). It is possible that
40mg per day allows the IM patients to have a steady state
concentration similar to EM or at least high enough to benefit from
the treatment.
Previous studies have shown that adjuvant tamoxifen users with
a PM status (only based on CYP2D6 genotype) have an increased
risk of breast cancer recurrence and mortality (Goetz et al, 2005;
Lim et al, 2007; Schroth et al, 2007; Bijl et al, 2009). In our study,
no association was found between solely CYP2D6 genotype and
TTP or OS in MBC patients. This may be explained by the
relatively small group of CYP2D6 PMs in our set of patients. An
alternative explanation can be that the effect of genotype observed
in the adjuvant setting is less pronounced in MBC. On the other
hand, with respect to the adjuvant setting, several other studies
also did not show an association between CYP2D6 genotype and
Table 2 CYP2D6-predicted phenotype based on the combination of the CYP2D6 genotype and concomitant use of a CYP2D6 inhibitor
CYP2D6 phenotype
a CYP2D6 genotype Strong inhibitor Moderate inhibitor Weak inhibitor N¼99 (%)
EM wt/wt No No No 41 (41.4)
wt/*10 No No No 2 (2.0)
wt/*41 No No No 5 (5.1)
IM wt/*3 No No No 1 (1.0)
wt/*4 No No No 25 (25.3)
wt/*5 No No No 3 (3.0)
wt/*6 No No No 1 (1.0)
*3/*41 No No No 1 (1.0)
*4/*10 No No No 1 (1.0)
*4/*41 No No No 4 (4.0)
wt/wt No No Yes 2 (2.0)
PM *3/*4 No No No 3 (3.0)
*3/*4 Yes No No 1 (1.0)
*4/*4 No No No 4 (4.0)
*4/*6 No No No 1 (1.0)
wt/*3 Yes No No 1 (1.0)
wt/*41 Yes No No 1 (1.0)
wt/wt Yes No No 2 (2.0)
Abbreviations: CYP2D6¼cytochrome P450 2D6; EM¼extensive metabolisers; IM¼intermediate metabolisers; PM¼poor metabolisers; wt¼wild type.
aOn the basis of
CYP2D6 genotype (CYP2D6*3, *4, *5, *6, *10 and *41) and concomitant use of CYP2D6-inhibiting medication.
Table 3 Association between CYP2D6 predicted phenotype, time to progression and overall survival
Time to progression Overall survival
CYP2D6 phenotype
a Cases (n¼99) HR
b (95% CI) P-value Cases (n¼67) HR
b (95% CI) P-value
EM 48 1.00 (ref) 33 1.00 (ref)
IM 38 0.99 (0.64–1.55) 0.98 22 0.87 (0.50–1.50) 0.62
PM 13 1.69 (0.90–3.19) 0.11 12 2.09 (1.06–4.12) 0.03
Abbreviations: CI¼confidence interval; CYP2D6¼cytochrome P450 2D6; EM¼extensive metabolisers; HR¼hazards ratio; IM¼intermediate metabolisers; PM¼poor
metabolisers; ref¼reference.
aOn the basis of CYP2D6 genotype (CYP2D6*3, *4, *5, *6, *10 and *41) and concomitant use of CYP2D6-inhibiting medication.
bHRs were
calculated using Cox-proportional hazards models and were adjusted for age at the index date.
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stamoxifen efficacy. In two studies on adjuvant tamoxifen treat-
ment, no differences were found in survival rates between PMs and
other metabolising groups (Nowell et al, 2005; Wegman et al,
2007). In another study, Wegman et al (2005)even showed a better
recurrence-free survival in PMs. The conflicting results may partly
be explained by differences or heterogeneity in study populations
and in view of our data also by lack of information about
concomitant use of CYP2D6 inhibitors and hormone receptor
status. Differences in dysfunctional alleles that have been studied
also make it difficult to compare the results and can cause
misinterpretation (Dezentje et al, 2009). The gene encoding for
CYP2D6 is highly polymorphic, with CYP2D6*4 being the most
common dysfunctional variant allele in Caucasians [5]. In our
study, besides CYP2D6 *4, also the CYP2D6 dysfunctional alleles
CYP2D6*3, *5, *6, *10 and *41 having a low allele frequency, have
been included in the analysis (Bradford, 2002).
Retrospective analyses clearly have shortcomings (that is,
incomplete information on breast cancer stage, tumour size or
nodal stage, or treatment given after progression on tamoxifen),
but for this study there is no reason to assume that these variables
differ significantly between the three phenotype groups nor have
influenced outcome (Schroth et al, 2007). In addition, information
about compliance may not have been complete as this was
gathered retrospectively from patient charts. In a study by Rae et al
(2009), an association between CYP2D6 genotype and compliance
to tamoxifen therapy was shown, as PMs were more likely to
continue tamoxifen therapy compared with intermediate or EMs.
The results suggest that EMs are more likely to both obtain benefit
from tamoxifen therapy and discontinue the drug because of side
effects (Rae et al, 2009). This implies that the observed effects of
tamoxifen in our study may even be underestimated by decreased
adherence or persistence to therapy. Regarding the inclusion
criteria there may have been selection bias, as not all patients may
have been included. In that case we would expect to now have
fewer PMs in the analysis compared with IMs or EMs, as they have
a shorter OS and may have died before inclusion took place. This
would also mean that our data may underestimate the effect
described.
Our results are in line with the findings by Kelly et al (2010),
who also found that tamoxifen may be less effective in patients
treated with tamoxifen while taking CYP2D6 inhibitors, although
the number of patients using this co-medication was relatively
small in our study group. Nevertheless, it is striking to notice that
relatively large differences in therapeutic outcome were found. For
treatment of hot flushes as a side effect of tamoxifen therapy SSRIs
are often prescribed (Goetz and Loprinzi, 2003). Clearly the
potential negative effect of such SSRIs on the efficacy of the anti-
cancer effect of tamoxifen is a matter of great concern. We could
not ascertain the indication for anti-depressant treatment to rule
out that the underlying disorder is responsible for the effect seen.
But as the findings by Kelly et al (2010) show an increased
mortality risk only with potent and not with weak or moderate
inhibitors of CYP2D6 showing a strong biological plausibility,
selection bias is not readily suggested. However, this will have to
be confirmed in prospective studies.
Although further research is needed, this may imply that
CYP2D6 EMs can preferentially be treated with tamoxifen instead
of aromatase inhibitors. On the other hand, CYP2D6 PMs and
patients who cannot avoid using CYP2D6-inhibiting medication
might benefit more from aromatase inhibitors over tamoxifen, as
these compounds have another metabolic route. Another option
might be to give an escalated tamoxifen dose to increase plasma
endoxifen concentrations. Tamoxifen doses higher than 40mg
daily may theoretically be necessary to achieve adequate plasma
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Figure 1 (A) Kaplan–Meier curves for time to progression and
(B) overall survival, based on CYP2D6-predicted phenotype. EM, extensive
metabolisers; IM, intermediate metabolisers; PM, poor metabolisers.
Table 4 Association between CYP2D6-inhibiting co-medication, time to progression and overall survival
Time to progression Overall survival
CYP2D6-inhibiting
Co-medication
a Cases (n¼102) HR
b (95% CI) P-value Cases (n¼70) HR
b (95% CI) P-value
No 95 1.00 (ref) 63 1.00 (ref)
Yes 7 2.97 (1.33–6.67) 0.008 7 3.55 (1.59–7.96) 0.002
Abbreviations: CI¼confidence interval; CYP2D6¼cytochrome P450 2D6; HR¼hazards ratio; ref¼reference.
aCo-medication: paroxetine (n¼4), fluoxetine (n¼1), sertraline
(n¼1) and citalopram (n¼1).
bHRs were calculated using Cox-proportional hazards models and were adjusted for genotype (PM, IM and EM based on CYP2D6*3, *4, *5 ,*6,
*10 and *41) and age at the index date.
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On the basis of our study and the current literature, we would
favour to study not only CYP2D6 genotype but to focus more on
CYP2D6 phenotype, thereby taking co-medication into account.
One way to do this is by giving the patient a CYP2D6 activity probe
drug that mimics the metabolism of tamoxifen (Mathijssen and
van Schaik, 2006). Currently, such a phenotyping study is ongoing
at our clinic (see http://www.trialregister.nl: NTR number 1751).
In addition, it would be of interest to further explore the role
of plasma concentrations of tamoxifen metabolites (that is,
endoxifen) as predictors of therapeutic outcome (Kiyotani et al,
2010). Therapeutic drug monitoring should therefore be included
in prospective studies that evaluate the effect of CYP2D6
phenotype on tamoxifen treatment outcome.
In summary, we showed that CYP2D6-predicted phenotype,
described as the combined effect of CYP2D6 genotype and
co-prescribed CYP2D6-inhibiting medication, is a predictor of
outcome in women using tamoxifen (40mg per day) for the
treatment of hormone receptor-positive MBC. As co-administra-
tion of CYP2D6-inhibiting medication seems to diminish the
treatment effect of tamoxifen, this combination of drugs should be
handled with care.
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